Reaching the Oncology Patients You Need is Just One Way We Take Care of Your Trial
Palleos Oncology™ is a dedicated solutions package aimed at helping pharma from early to late stage oncology treatment development.
21 years of Oncology Expertise
We provide a full range of high-quality clinical trial services for Phase I-IV and BE studies. We offer both full-service clinical study engagements and stand alone services in a number of therapeutic areas.
By Cancer Type
- Breast Cancer
- Lung Cancer
- Solid Tumor
- Blood Cancer
- Ovarian Cancer
- Other types
Experience by Phase
- Phase I
- Phase II
- Phase III
- Phase IV (post-marketing)
Trusted by Leading Pharma Companies
We partner with pharmaceutical and biotech organizations worldwide
On Average 1.5x Faster Enrollment Rate Compared to Other Regions
Colorectal Cancer
Patients / Site / MonthPh3 Breast Cancer
Ph3 Ovarian Cancer
Ph3 Non-small Lung Cancer
Special Expertise in Immuno-Oncology Studies
Succeeding in target treatment development dictates the use of innovative methods to quickly identify and deliver the right therapy to the right patient. Within our vast portfolio of oncology studies, we are proud to offer adequate expertise in immuno-oncology studies. Look at the snapshot with our most prominent cases in this area.
| Studies | Phase | Year | Patients* | Status |
|---|---|---|---|---|
| NSCLC | III | 2019 | 360 | Ongoing |
| Solid Tumor / NSCLC (with high PD-L1 expression) (Anti PD-L1 antibody) | I | 2018 | 104 | Ongoing |
| Non-Hodgkin’s Lymphoma (Anti CD-20) | II | 2017 | 50 | Complete |
| Chronic Lymphocytic Leukemia (Anti-CD20 mAB + PI3K kinase inhibitor) | III | 2016 | 30 | Ongoing |
| B-cell Lymphoma (Rituximab) | II | 2016 | 104 | Ongoing |
| Non-small cell lung and Epithelial ovarian cancer (PD-L1 inhibitor) | I | 2013 | 60 | Complete |
| Solid Tumors (PD-L1 inhibitor) | I | 2013 | 40 | Complete |
| Locally Advanced Pancreatic Cancer (Onco-vaccine) | II | 2011 | 40 | Complete |
* Number of patients recruited by Palleos
Why Our Clients Choose Palleos
45 different indications, including Ovarian Cancer, Non-Small Cell Lung Cancer, Head & Neck Cancer, and Solid Tumors
35,466 Patients
successfully enrolled across 80 completed oncology studies
300 clinics in 12 countries
vast investigator network across Central and Eastern Europe
76% of Studies
are completed on time and on budget
Seamless Communication
Efficient communication prevents lagging due to mismanagement and ensures that sponsors have a cooperative experience
Transparent Pricing
our budgets consist of more than 400 cost items, which makes budget planning more accurate and efficient
A Dedicated Project Team
Including Oncology medical experts and experienced CRAs
Your Study Lifecycle with Palleos
From feasibility to success — we guide your oncology trial through every stage
Free Feasibility Report
Comprehensive site and patient analysis
Start Up
Regulatory submissions and site activation
Study Conduct
Patient enrollment and data collection
Data Analysis
Statistical analysis and reporting
Regulatory Submissions
Dossier preparation and filing
Post Submission
Authority queries and follow-up
Study Success
Approval and market success
For us, quality and trial KPIs are not a trade-off. We deliver the best across the board — trial execution, budget, and timeline.
Philip Raeth
Managing Director
See the Stories of the Clients Who Chose Palleos Oncology™
Palleos is privileged to support global pharmaceutical companies and biotechs, and with this experience we can help you follow the right steps towards faster treatment approvals, so medicines can reach patients more rapidly.
Relationships Are Important to Us
Reach out to us to learn more about how our approach, experience, investigator relationships, bid transparency and flexibility deliver success for our clients.
Let’s start a new study together
